Brief: Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared To Pembrolizumab Monotherapy In Pd-L1-Positive Advanced Nsclc In Harmoni-2 Study Conducted By Akeso In China
02/09/2026 22:56
BRIEF-Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared To Pembrolizumab Monotherapy In Pd-L1-Positive Advanced Nsclc In Harmoni-2 Study Conducted By Akeso In China Sept 2 (Reuters) - Summit Therapeutics Inc. SMMT.O:
IVONESCIMAB MONOTHERAPY DEMONSTRATES STATISTICALLY SIGNIFICANT OVERALL SURVIVAL BENEFIT COMPARED TO PEMBROLIZUMAB MONOTHERAPY IN PD-L1-POSITIVE ADVANCED NSCLC IN HARMONI-2 STUDY CONDUCTED BY AKESO IN CHINA
Source text: ID:nBw167zY6a
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)